Meeting
2021 ASCO Annual Meeting
Differentiated activity profile for the PD-1 inhibitor balstilimab.
Authors
Cailin Joyce
Agenus Inc., Lexington, MA
Cailin Joyce , Dhan Chand , Benjamin Duckless , Manuel Hidalgo , Joseph Elan Grossman , Remigiusz Kaleta , David M. O'Malley
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Cervical Cancer
Clinical Trial Registration Number
NCT03104699
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 5529)
DOI
10.1200/JCO.2021.39.15_suppl.5529
Abstract #
5529
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2017 Genitourinary Cancers Symposium
Impact of immune checkpoint protein expression in tumor cells and tumor infiltrating CD8+ T cells on clinical benefit from PD-1 blockade in metastatic clear cell renal cell carcinoma (mccRCC).
First Author: Jean-Christophe Pignon
Poster
2024 ASCO Genitourinary Cancers Symposium
Preclinical testing of a novel PD-L1 inhibitor for the treatment of renal cell carcinoma.
First Author: Michelle Hsu
Poster
2022 ASCO Annual Meeting
Characterization of NY-ESO-1 gene expression in gastric cancer (GC).
First Author: Annika Lenz
Poster
2017 ASCO Annual Meeting
Phase II clinical trial of atezolizumab (A) in advanced non-small cell lung cancer (NSCLC) patients (pts) previously treated with PD1-directed therapy.
First Author: Saveri Bhattacharya